Side Area Logo
Welcome to unde omnis iste natus error sit voluptatem accusantium
Keep conected


Windtree Therapeutics, Inc. is a biotechnology company focused on developing novel KL4 surfactant therapies for respiratory diseases and other potential applications. Windtree’s proprietary technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant ) that is structurally similar to human pulmonary surfactant — and novel drug-delivery technologies that are being developed to enable noninvasive administration of aerosolized KL4 surfactant. Windtree is focused initially on improving the management of respiratory distress syndrome (RDS) in premature infants as surfactant therapy has been shown to save lives in this condition. Windtree believes that its proprietary technologies may make it possible, over time, to develop a pipeline of KL4 surfactant product candidates to address a variety of respiratory diseases for which there are few or no approved therapies and, in doing so, potentially deliver a lifetime of hope to patients and their families.


Windtree Therapeutics’ technology platform includes it’s novel proprietary
surfactant and proprietary drug delivery technologies.

KL4 Surfactant

Aerosol Drug Delivery

 Our mission is clear – remove the barriers to early intervention with surfactant therapy among premature infants whose long-term health is often defined in the first hours of life. 

Craig Fraser, Chief Executive Officer

News and Events

Press Releases

RSS Press Releases | Windtree Therapeutics

Corporate Presentation

Corporate Presentation